In cancer cells, the long-term effects of pyrazinoylguanidine-type NHE1 inhibitors, which have generally been assumed to be downstream of NHE1 inhibition, include decreased proliferation, reduced metastatic potential and -viability, and sensitization to chemotherapy32,45,47,48. Here, SLC9A1 is linked to cancer.